治疗抗中性粒细胞胞浆抗体相关性血管炎的C5a受体抑制剂:avacopan  

C5a receptor inhibitor avacopan in treatment of anti-neutrophil cytoplasmic antibodies-associated vasculitis

作　　者：席勤妹 李万鹏[2] XI Qin-mei;LI Wan-peng(Department of Geriatrics,Gansu Provincial Hospital,Lanzhou GANSU 730013,China;Department of Cardiology,Gansu Provincial Hospital,Lanzhou GANSU 730013,China)

机构地区：[1]甘肃省人民医院老年病科,甘肃兰州730013 [2]甘肃省人民医院心血管内科,甘肃兰州730013

出　　处：《中国新药与临床杂志》2023年第5期289-292,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)是一组罕见的异质性疾病,以血管炎症为特征,可危及患者生命,目前治疗AAV主要依靠激素。促炎补体C5a及其受体在AAV发病机制中发挥重要作用。avacopan是一种口服C5a受体抑制剂,于2021年10月获美国食品和药物管理局批准上市,用于成人严重活动性ANCA相关的镜下多血管炎和肉芽肿伴多血管炎等的辅助治疗,与激素标准疗法联用。临床试验显示,avacopan能有效缓解AAV,改善肾响应率和临床反应率,安全性良好,可减少对激素疗法的依赖,主要不良事件包括高血压和血管炎恶化。Anti-neutrophil cytoplasmic antibody(ANCA)-associated vasculitis(AAV)is a group of rare heterogeneous diseases featuring the life-threatening blood vessel inflammation.Current therapies against AAV rely on glucocorticord.The proinflammatory complement C5a and its receptor play an important role in the pathogenesis of AAV.Avacopan,an oral C5a receptor inhibitor,was approved by the U.S.Food and Drug Administration in October 2021,as an adjunctive treatment in adults for such severe active ANCA-associated vasculitis as microscopic polyangitis and granulomatosis with polyangitis in combination with standard therapy including glucocorticoids.Clinical trials showed that avacopan can effectively alleviate AAV,improve renal response rate and clinical response rate,with good safety profile.It can reduce dependence on hormone therapy.The drug-related adverse events comprises the hypertension and the worsen vasculitis.

关 键 词：avacopan 抗中性粒细胞胞浆相关性血管炎 补体C5 C5A受体 

分 类 号：R543[医药卫生—心血管疾病] R963[医药卫生—内科学]